A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)

• Status: Completed
• Trial end date: 2005-07-01

Summary

To determine the safety and tolerability of single oral doses of HPN-100 as a formulation (GT4P-F) and GT4P as the active pharmaceutical ingredient (GT4P-API) administered to healthy male subjects.

• Phase: Phase 1

Details

• Lead Sponsor: Horizon Pharma Ireland, Ltd., Dublin Ireland
• Collaborator: Ucyclyd Pharma, Inc.
• Treatments: 4-phenylbutyric acid; Phenylacetic acid; Sodium Benzoate